Lauxera Capital Partners

OrganOx Limited, founded in 2008 and based in Oxford, United Kingdom, specializes in organ preservation and transplantation technology, particularly for liver transplants. The company has developed the Metra device, which employs normothermic preservation technology to store livers outside the body at normal body temperature. This innovative approach mimics the conditions of the human body by continuously perfusing the liver with oxygen-carrying red cells and nutrients, thereby preventing the decay of the organ before transplantation. The Metra device enables the liver to produce bile, metabolize glucose, and maintain a physiological pH level, ultimately enhancing the viability of the organ for transplant. OrganOx's research and development efforts are rooted in the work of Prof Peter Friend and Prof Constantin Coussios at the University of Oxford.

Acandis GmbH is a manufacturer of medical devices focused on treating neurovascular diseases. The company develops a range of products, including Engineering Stroke Solutions, Flow Diverters, Stent Retrievers, and Embolisation Devices, aimed at enhancing acute stroke care and thrombectomy procedures. Acandis is dedicated to providing innovative and user-oriented solutions that address the technical and medical challenges faced by neuroradiologists. Their comprehensive understanding of symptoms, diagnostics, and treatment options enables them to create devices that improve patient outcomes in the field of neurovascular health.

Synovo Group specializes in providing digital services and software solutions tailored for medical transport professionals. The company facilitates digital transitions for businesses by offering a comprehensive suite of services, including IT management, telecom, cloud services, and infrastructure hosting. Additionally, Synovo Group ensures compliance with health data hosting standards through its HDS-certified services. Its offerings encompass hosting and outsourcing solutions, security consultancy, and the sale of IT hardware and software, all designed to enhance the operational efficiency of logistics within the medical transport sector.

Natural Cycles is a digital health company that provides a contraceptive app designed to empower women in managing their reproductive health. The app utilizes an algorithm to analyze users' basal body temperature and other relevant data, such as luteinizing hormone levels, to determine fertility status throughout the menstrual cycle. By requiring daily temperature measurements with a basal thermometer, the app generates a color-coded calendar that informs users of their fertile days, allowing for informed decisions regarding unprotected sex. This non-invasive and non-hormonal approach enables women to plan or prevent pregnancies while avoiding the side effects associated with traditional contraceptive methods. Natural Cycles is at the forefront of digital contraception, offering a modern solution to female fertility tracking.

BioLamina AB is a biotechnology company based in Sundbyberg, Sweden, established in 2009. The company specializes in the development, manufacture, marketing, and sale of laminin cell culture products that facilitate the growth of stem cells and tissue-specific cells. Its offerings include a variety of defined human recombinant laminin matrices that enable precise control in cell culture applications, including human and mouse embryonic stem cell culturing, the creation of beta cell islets, and clonal culturing of human embryonic stem cells. BioLamina's products are designed to imitate natural cell-specific matrix interactions, thereby enhancing the functionality of primary cells and assisting in the development of clinically compliant cell therapies. The company also maintains a strategic collaboration with CEVEC Pharmaceuticals GmbH to further its research and product offerings.

OrganOx Limited, founded in 2008 and based in Oxford, United Kingdom, specializes in organ preservation and transplantation technology, particularly for liver transplants. The company has developed the Metra device, which employs normothermic preservation technology to store livers outside the body at normal body temperature. This innovative approach mimics the conditions of the human body by continuously perfusing the liver with oxygen-carrying red cells and nutrients, thereby preventing the decay of the organ before transplantation. The Metra device enables the liver to produce bile, metabolize glucose, and maintain a physiological pH level, ultimately enhancing the viability of the organ for transplant. OrganOx's research and development efforts are rooted in the work of Prof Peter Friend and Prof Constantin Coussios at the University of Oxford.

Matrix Requirements GmbH is a global software company specializing in quality management solutions for medical device manufacturers. Its flagship products, MatrixALM and MatrixQMS, facilitate compliance with regulatory standards while promoting agile development practices. By integrating quality management across the entire product lifecycle, Matrix Requirements helps companies efficiently manage specifications, risks, and testing processes. The company is certified in EN ISO 13485:2016 and ISO/IEC 27001:2013, underscoring its commitment to quality and security in the medical technology sector. For more information, visit www.matrixreq.com.

Veranex is a global service provider that specializes in the medical technology sector, offering comprehensive, technology-enabled solutions from concept to commercialization. The company focuses exclusively on various areas within medical technology, including medical devices, diagnostics, companion diagnostics, digital health, and drug delivery. Veranex provides a wide range of services, such as design and engineering, regulatory support, clinical trials, and market access, enabling clients to streamline their development processes. By addressing the entire clinical trial journey, Veranex helps clients accelerate their time to market, enhance market viability, manage development costs, and reduce associated risks.

Lifen is a Paris-based startup focused on enhancing digital solutions for hospitals, doctors, and patients. Established in 2015, Lifen specializes in simplifying the sharing of medical data and has become a leading operator of MSSanté in France, partnering with over 600 healthcare establishments. The company facilitates the transmission of approximately 2 million medical documents monthly to around 240,000 doctors. Lifen has developed a healthcare data management platform that includes a mail assistant for creating secure medical email addresses, reducing reliance on paper mail, and optimizing communication methods among healthcare practitioners. Recognized for its contributions to interoperability, Lifen aims to leverage its expertise to create a platform that simplifies the integration and operational deployment of various digital solutions in the healthcare sector.

Groupe PSIH provides healthcare data hosting and management services for managing activities of hospitals.

Caresyntax Inc. is a Boston-based company that provides a digital surgery platform to enhance surgical performance in hospitals and ambulatory surgical centers. Founded in 1991, it leverages data from over 1,600 hospitals globally to deliver insights that improve patient outcomes and operational efficiency. The platform integrates various data sources, including video, audio, clinical, and operational data, enabling real-time analysis and decision-making during surgeries. Caresyntax offers solutions such as qvident, a performance management software, and PRIME365, a comprehensive integration platform that consolidates surgical data and content. With a focus on automating workflows and reducing surgical variability, Caresyntax supports over 4,000 operating rooms and has facilitated millions of surgical procedures worldwide. The company’s HIPAA-compliant software can be deployed on-premise, in the cloud, or in a hybrid format, making it adaptable to diverse healthcare environments.

LUMICKS specializes in advanced technologies for studying biology and cancer at the single-molecule and single-cell levels. The company focuses on bridging the gap between molecular structure and function, providing tools that enable real-time analysis of complex biological processes. Its flagship product, the C-Trap Optical Tweezers, combined with Fluorescence Microscopy, allows scientists to observe interactions at the single-molecule level. Additionally, the z-Movi Cell Avidity Analyzer measures and selects immune cells based on their real-time interactions with target cells. By facilitating live measurement and imaging, LUMICKS' instruments provide critical insights into the fundamental causes of diseases, including cancer, and hold potential for optimizing drug development.

Reapplix ApS, founded in 2008 and based in Birkerod, Denmark, is a research and development company focused on improving wound healing through the use of blood-derived proteins. The company identifies and isolates these proteins to create a tissue regeneration device that provides biological treatment for chronic wounds, particularly diabetic foot ulcers. By utilizing a platform that delivers evidence-based biological wound therapy made entirely from a patient's own blood, Reapplix enables hospitals to offer autologous active cell therapy. This approach allows patients to leverage their own biological materials for enhanced healing outcomes.